Not applicable.
1. Field of the Art
Embodiments of the present invention generally relate to biomedical membranes and, in particular, to ultrathin (e.g., between 0.01 μm to 5 μm thick) parylene C membranes that have exhibited permeability that is ideal for monolayer biological cell growth.
2. Description of the Related Art
Biological cells are often grown on membranes. For optimal growth of on on-membrane cell culture, the membranes must be permeable to nutrients (and waste from cells), such as proteins in serum. Membranes with pores that are large enough to allow proteins to flow through are used extensively in laboratories and are finding new applications as analysis equipment becomes smaller and more efficient.
Porous membranes are widely used in Micro Total Analysis System (μTAS) and Lab-on-a-Chip (LOC) applications, allowing chemical or biological reagents transportations and filtration. Among different types of membranes, commercially available track-etched porous membranes are one of the most popular choices, with various sizes of holes in submicron and micron (μm) ranges. Track etching involves heavy-ion bombardment of thin films and then chemical etching to reveal the tracks into holes.
Parylene, a generic name for members of a series of poly(p-xylylene) polymers, is generally biocompatible. Of the common types of parylene, parylene C is perhaps the most widely used in industry. Parylene C is sometimes referred to with a dash, i.e., “parylene-C,” and sometimes is abbreviated as “PA-C.” Its demonstrated bio-compatibility as a United States Pharmacopeial Convention (USP) Class VI biocompatible polymer makes it suitable for medical devices. However, it is not porous or considered permeable. In fact, it is used extensively in industry as a conformal coating for electronics and medical devices because it is water tight and essentially pinhole-free when chemical vapor deposited in extremely thin layers.
Generally, devices, systems, and methods for manufacturing a semipermeable parylene C membrane are disclosed. Parylene C—which has been found to be permeable to proteins in serum at ultrathin thicknesses (e.g., 0.01 μm to 5 μm thick)—is manufactured into a membrane having a smooth front side and tiny hills and valleys on the back side, such that it has a variable thickness. The hills and valleys, which can be stepwise-edged like a city skyline or histogram, can be manufactured using lithographic techniques.
One way of manufacturing such a membrane is to etch a relatively thick parylene film with tiny, through-hole perforations, lay it on a smooth substrate, and deposit an ultrathin layer of parylene over the perforated thick layer. The resulting parylene membrane is then peeled off of the substrate. The side of the membrane that was against the substrate is smooth, as the ultrathin layer of parylene covers the openings of the perforations. The opposite side of the membrane remains rough with hills and valleys because the ultrathin layer of deposited parylene was not enough material to fill in the etched perforations.
Embodiments of the present invention relate to a synthetic semipermeable membrane apparatus. The apparatus includes a membrane having a smooth front side, a back side, and spatially interspersed thin and thick regions between the smooth front side and the back side, the thin regions being a predetermined thickness of parylene, the predetermined thickness selected from a thickness between 0.01 μm to 5 μm, such as 0.01, 0.1, 0.2, 0.3, 0.4, 0.5, 0.6, 0.7, 0.8, 0.9, 1.0, 1.2, 1.4, 1.6, 1.8, 2.0, 2.2, 2.4, 2.6, 2.8, 3.0, 3.2, 3.4, 3.6, 3.8, 4.0, 4.2, 4.4, 4.6, and 4.8 μm. The thick regions comprise parylene or another material and are at least 2 times thicker than the predetermined thickness of the thin regions, and the interspersion of the thin and thick regions occur in a random or patterned array with an average feature size of about 1 μm to 10 μm, such as 1, 2, 3, 4, 5, 6, 7, 8, 9, or 10 μm.
Some embodiments relate to a synthetic semipermeable membrane apparatus, including a supporting film having a plurality of through perforations extending from a first side to an opposing, second side of the supporting film, and a 0.01- to 5-μm (or 0.01, 0.1, 0.2, 0.3, 0.4, 0.5, 0.6, 0.7, 0.8, 0.9, 1.0, 1.2, 1.4, 1.6, 1.8, 2.0, 2.2, 2.4, 2.6, 2.8, 3.0, 3.2, 3.4, 3.6, 3.8, 4.0, 4.2, 4.4, 4.6, and 4.8 μm) thin parylene layer covering an opening of each perforation of the supporting film.
Some embodiments relate to a process for fabricating a synthetic semipermeable membrane. The process includes providing a supporting film having through perforations extending from a first side to an opposing, second side of the supporting film, laying the first side of the supporting film against a smooth substrate surface, depositing a 0.01- to 5-μm (or 0.01, 0.1, 0.2, 0.3, 0.4, 0.5, 0.6, 0.7, 0.8, 0.9, 1.0, 1.2, 1.4, 1.6, 1.8, 2.0, 2.2, 2.4, 2.6, 2.8, 3.0, 3.2, 3.4, 3.6, 3.8, 4.0, 4.2, 4.4, 4.6, and 4.8 μm) thin parylene layer over the supporting film sufficient to cover a bottom of each perforation of the supporting film to form a membrane with a smooth first side, and removing the membrane from the smooth substrate surface.
Some embodiments relate to a method of using a synthetic semipermeable membrane, the method including providing a membrane that has a supporting film having a plurality of through perforations extending from a first side to an opposing, second side of the supporting film and a 0.01- to 5-μm (or 0.01, 0.1, 0.2, 0.3, 0.4, 0.5, 0.6, 0.7, 0.8, 0.9, 1.0, 1.2, 1.4, 1.6, 1.8, 2.0, 2.2, 2.4, 2.6, 2.8, 3.0, 3.2, 3.4, 3.6, 3.8, 4.0, 4.2, 4.4, 4.6, 4.8 and 5.0 μm) thin parylene layer covering an opening of each perforation of the supporting film wherein the covered openings of the perforations are even with a surface of the first side of the supporting film, thereby forming a substantially smooth surface on the first side. The method further includes diffusing molecules through the membrane.
Reference to the remaining portions of the specification, including the drawings and claims, will realize other features and advantages of the present invention. Further features and advantages of the present invention, as well as the structure and operation of various embodiments of the present invention, are described in detail below with respect to the accompanying drawings. In the drawings, like reference numbers indicate identical or functionally similar elements.
Generally, devices, systems, and methods for manufacturing a semipermeable parylene C membrane are disclosed. A membrane with ultrathin (e.g., 0.01 μm to 5 μm thick) parylene regions is arranged to have a smooth side and a spatially variable thickness. The smooth side can be used to grow a monolayer of cells, while the bumps or undulations on the second side prevent cell growth on the second side. The ultrathin portions of the parylene are permeable to protein-sized molecules but impermeable to cells, which are on the order of 4 μm (for tiny photoreceptor rod and cone cells of the retina) to greater than 20 μm. The thicker portions of the membrane, which are interspersed with the thin portions, make the membrane stronger, less prone to folding or undulating, and generally easier to handle for surgeons.
Prior art porous membranes have been found to have disadvantages. First, the fabrication of small holes (i.e., <0.1 μm) is difficult to perform reliably. Therefore, in some applications where the cut-off selective size of the particles has to be smaller than 0.1 μm, porous membranes usually are not capable for biological applications. Second, when used in on-membrane cell culture applications, the porous topology may disturb the adherence and morphology of biological cells. The nooks and crannies of the pores present a non-smooth, variable surface, which is suboptimal for the growth of even cell monolayers. This can make the in vitro cultured cells very different from cells growing in their in vivo natural environment.
Materials that are naturally semipermeable are known, such as collagen and polydimethylsiloxane (PDMS). However, the surfaces of these semipermeable materials are often sponge-like. They are often not biocompatible, so they are not proper for implantation applications. Furthermore, they are difficult to reliably pattern into desired shapes and designs.
Parylene (including all the parylene derivatives such as parylene N, C, D, HT, AM, A, etc.) has been shown to be a superior biocompatible material, but it is usually used as a protective coating to prevent harmful large molecules from going through it. The inventors have not only determined how to use parylene as a permeable material, but they have also performed an in-depth study of the permeability of ultrathin parylene C to optimize the “thickness design” of parylene semi-permeable membranes. It has been found that parylene is permeable below some thicknesses, and the thinner the parylene, the more permeable it is. Furthermore, it is proposed that parylenes with thicknesses from 0.01 μm to 5 μm (or 0.01, 0.1, 0.2, 0.3, 0.4, 0.5, 0.6, 0.7, 0.8, 0.9, 1.0, 1.2, 1.4, 1.6, 1.8, 2.0, 2.2, 2.4, 2.6, 2.8, 3.0, 3.2, 3.4, 3.6, 3.8, 4.0, 4.2, 4.4, 4.6, and 4.8 μm) can readily be used as semipermeable membranes in medical applications when coupled with thicker frames and supporting films.
Technical advantages of some of the embodiments are many. The smooth surface of the front side of a membrane is advantageous for cell growth than rough or spongy surfaces. The thin parylene areas allow nutrients and cell waste to pass through the membrane, while the thick areas give mechanical support and rigidity so that the membrane is less prone to tearing, folding, undulating, etc. during implantation. The thickness of the ultrathin parylene can be scaled for growing any cell type in a monolayer for implantation in the body. For example, retinal pigment epithelium (RPE) can be grown in a monolayer on the membrane. Cartilage trabeculae, heart muscle, and other cells can be grown in a monolayer as well. Besides facilitating in vitro perfusion cell culture, semipermeable parylene-C membrane also has use in the in vivo replacement of a Bruch's membrane in the eye for age-related macular degeneration. Bruch's membrane allows the passage of molecules with MW below 75 kDa.
An embodiment may be able to replace impaired human semipermeable tissue membranes anywhere in the human body, not just the Bruch's membrane. For example, the human lens capsule and collagen film can use parylene C membranes thinner than 0.30 μm.
As a proof of design, ultrathin parylene C membranes with thicknesses ranging from 0.15 μm to 0.80 μm have been experimentally verified. At least four different thicknesses (i.e., 0.15 μm, 0.30 μm, 0.50 μm, and 0.80 μm) of parylene C membranes manufactured on perforated support films were subject to diffusion studies using fluorescein isothiocyanate (FITC)-dextran molecules of different molecular weights (MWs) at body temperature (37° C.; 98.6° F.). A diffusion coefficients for each of five molecules (i.e. 10 kDa, 40 kDa, 70 kDa, 125 kDa, and 250 kDa) was obtained by fitting concentration-time curves into the equation:
where C0 is the initial concentration on a first side of the membrane, C2 is the concentration on the second side of the membrane (where C2 at the start of each experiment is 0), V1 and V2 are the volumes of liquid on the respective sides of the membrane and V=V1+V2 (i.e., the total volume), h is the thickness of the ultrathin regions of the membrane (i.e., 0.15 μm, 0.30 μm, 0.50 μm, and 0.80 μm), and Aeff is the effective area of the ultrathin portion of the membrane.
Because the membrane's thick regions were 20-μm diameter holes with a center-to-center spacing of 30 μm, Aeff for all the tested membranes is:
After obtaining the diffusion coefficients, the theoretical MW exclusion limit was then calculated for each thickness of film by extrapolating the linear relationship between the diffusion coefficients and the natural log of MW (i.e., ln(MW)) to a diffusion coefficient of zero. The results of this calculation are tabled in Table 1. Also tabled are respective exclusion radiuses (and diameters), calculated from the MWs of the FITC-dextran molecules.
Determining exclusion diameters of certain thicknesses of parylene is only part of the solution. While an ultrathin material may work in a laboratory, it may not be suitable in real-world situations.
Working with extremely thin parylene is difficult. To facilitate and strengthen the mechanical bending, stretching, and handling of ultrathin parylene, a thick supporting substrate design is disclosed. The supporting substrate is preferably thicker (e.g., 1-30 μm) than the ultrathin layers, such as two times as thick as the ultrathin layer. It can have various geometries, such as a mesh, net, pore, etc. geometry.
Further, a new substrate having an ultrathin parylene membrane with its back filled with some extremely permeable materials, such as silicone or hydrogels, is proposed for certain applications.
U.S. Patent Application Publication No. 2011/0236461 A1 to Coffey et al., published Sep. 29, 2011 (hereinafter “Coffey”), describes a polymer membrane for supporting the growth of retinal pigmented epithelial (RPE) cells in the human eye. Coffey discloses membrane pores between 0.2 μm and 0.5 μm in diameter (Coffey paragraph [0009]). The pore diameters in Coffey are substantially larger than exclusion diameters present in parylene C at the 0.01- to 5-μm thicknesses presented in this application (e.g., 0.0512 μm diameter; see Table 1). Furthermore, Coffey teaches that its membrane is preferably made from a hydrophilic polymer, such as polyester (see, e.g., Coffey paragraphs [0024] and [0043]), where parylene is characteristically hydrophobic.
The figures will be used to further describe aspects of the application.
Biocompatible membrane system 100 includes membrane 101 having a front, top side 104 and a back, bottom side 105. Orientation terms of “front,” “top,” “back,” “bottom,” etc. are for the convenience of the reader and are not limiting as to absolute orientation. Front side 104 is smooth, having no salient protrusions or recesses that inhibit the natural formation of cells growing as a monolayer. Back side 105 is relatively rough, inhibiting or reducing the growth of cells.
Membrane 101 includes thin regions 102 interspersed with thick regions 103. In this embodiment, thick regions 103 are substantially contiguous with one another, and thin regions 102 comprise cylindrical recesses in the membrane. Thin regions 102 are interspersed in a regular, grid-like patterned array on membrane 101. In some embodiments, a random array, as opposed to one with a recognizable pattern, can be interspersed on the membrane. Embodiments having a combination of patterned and random arrays are also contemplated.
On front side 104, thin regions 102 flow cleanly with thick regions 103 to form a smooth surface as shown in
The thin regions are of a predetermined thickness, predetermined based on a permeability desired. For example, to allow proteins having a molecular weight of 70 kDa or smaller to flow through while inhibiting molecules having a molecular weight of over 100 kDa, the thickness of the thin regions can be engineered to be 0.80 μm thick (see Table 1).
The thick regions can be 2, 3, 4, 5, or 10 (and gradations in between) or more times thicker than the thin sections. Their increased thickness allows the entire membrane to be more easily handled. In the exemplary embodiment, thick regions 103 are 3 times the thickness of thin regions 102. In certain applications, thicknesses of more than 6 μm may be unwieldy. In some other cases, thick region thicknesses between 1 μm and 30 μm (such as 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, and 29 μm) thick can be used.
In other embodiments, the thin regions can be substantially contiguous with one another, with the thick regions comprising protrusions from the back side of the membrane. That is, instead of a bunch of holes as shown in
“Substantially contiguous” regions include those that are flat with respect to each other without barriers or whose barriers are less than 10, 15, 20, or 25% of the respective regions' widths or as otherwise known in the art.
In
In
As shown in
As shown in
Manufactured membrane 401 has front side 404 (on the bottom in the figure) and back side 405 (on the top in the figure). Thin sections 402 are interlaced with thick sections 403 in pattern 428.
Tab 541 allows a surgeon's forceps or tool to hold the membrane, with cut-off section 542, or as otherwise described in U.S. Patent Application No. 61/481,037, filed Apr. 29, 2011.
Near circumference ring 640, membrane 601 includes thick regions 603 that have rectangular cross sections. Farther away from circumference ring 640, near the center of membrane 601, are thick regions 643 having rounded cross sections. Thick regions 603 have relatively sharp features with respect to thick regions 643, and thick regions 643 have relatively smooth features in comparison with thick regions 603.
Having relatively sharp regions near the circumference can retard or prevent cells that do happen to migrating around the edges of the membrane from growing on the membrane. Near the center, where there is less of a chance of cells migrating, the hills and valleys of the thick and thin regions can be smooth so that the membrane is better accepted during implantation and more compatible with the body.
The invention has been described with reference to various specific and illustrative embodiments. However, it should be understood that many variations and modifications may be made while remaining within the spirit and scope of the following claims.
This application is a continuation of U.S. patent application Ser. No. 14/498,918, filed on Sep. 26, 2014 (abandonded), which is a continuation of U.S. patent application Ser. No. 13/355,426, filed on Jan. 20, 2012 (issued as U.S. Pat. No. 8,877,489), which claims the benefit of U.S. Provisional Patent Application No. 61/566,965, filed Dec. 5, 2011, and it is a continuation of U.S. patent application Ser. No. 14/314,994, filed on Jun. 25, 2014 (issued as U.S. Pat. No. 10,188,769), each of which is hereby incorporated by reference in its entirety for all purposes. International Application No. PCT/US2011/043747, filed Jul. 12, 2011, and U.S. Provisional Application No. 61/481,037, filed Apr. 29, 2011, are hereby incorporated by reference in their entireties for all purposes.
Number | Name | Date | Kind |
---|---|---|---|
4047532 | Phillips et al. | Sep 1977 | A |
4700298 | Palcic et al. | Oct 1987 | A |
4715373 | Mazzocco et al. | Dec 1987 | A |
5024223 | Chow | Jun 1991 | A |
5196003 | Bilweis | Mar 1993 | A |
5688264 | Simon et al. | Nov 1997 | A |
5843780 | Thomson et al. | Dec 1998 | A |
6117675 | Van Der et al. | Sep 2000 | A |
6156042 | Aramant et al. | Dec 2000 | A |
6200806 | Thomson | Mar 2001 | B1 |
6231879 | Li et al. | May 2001 | B1 |
6254628 | Wallace et al. | Jul 2001 | B1 |
6264941 | Baetge et al. | Jul 2001 | B1 |
6299895 | Hammang et al. | Oct 2001 | B1 |
6303136 | Li et al. | Oct 2001 | B1 |
6322804 | Dionne et al. | Nov 2001 | B1 |
6337198 | Levene et al. | Jan 2002 | B1 |
6361771 | Tao et al. | Mar 2002 | B1 |
6436427 | Hammang et al. | Aug 2002 | B1 |
6582903 | Rigler et al. | Jun 2003 | B1 |
6627422 | Li et al. | Sep 2003 | B1 |
6642048 | Xu et al. | Nov 2003 | B2 |
6649184 | Hammang et al. | Nov 2003 | B2 |
6667176 | Funk et al. | Dec 2003 | B1 |
6669719 | Wallace et al. | Dec 2003 | B2 |
6712837 | Akerfeldt et al. | Mar 2004 | B2 |
6800480 | Bodnar et al. | Oct 2004 | B1 |
6833269 | Carpenter et al. | Dec 2004 | B2 |
6852527 | Chan et al. | Feb 2005 | B2 |
6875607 | Reubinoff et al. | Apr 2005 | B1 |
6939378 | Fishman et al. | Sep 2005 | B2 |
6942873 | Russell et al. | Sep 2005 | B2 |
7005252 | Thomson | Feb 2006 | B1 |
7011828 | Reubinoff et al. | Mar 2006 | B2 |
7029913 | Thomson et al. | Apr 2006 | B2 |
7107124 | Green | Sep 2006 | B2 |
7115257 | Tao et al. | Oct 2006 | B1 |
7135172 | Loftus et al. | Nov 2006 | B1 |
7141369 | Cao | Nov 2006 | B2 |
7147648 | Lin | Dec 2006 | B2 |
7217569 | Thomson | May 2007 | B2 |
7250294 | Carpenter et al. | Jul 2007 | B2 |
7297539 | Mandalam et al. | Nov 2007 | B2 |
7384426 | Wallace et al. | Jun 2008 | B2 |
7410798 | Mandalam et al. | Aug 2008 | B2 |
7413734 | Mistry et al. | Aug 2008 | B2 |
7413902 | Bodnar et al. | Aug 2008 | B2 |
7439064 | Thomson et al. | Oct 2008 | B2 |
7455983 | Xu et al. | Nov 2008 | B2 |
7504257 | Reubinoff et al. | Mar 2009 | B2 |
7541186 | Reh et al. | Jun 2009 | B2 |
7582479 | Thomson et al. | Sep 2009 | B2 |
7601525 | Batich et al. | Oct 2009 | B2 |
7604992 | Reubinoff | Oct 2009 | B2 |
7695967 | Russell et al. | Apr 2010 | B1 |
7736896 | Klimanskaya et al. | Jun 2010 | B2 |
7749726 | Chuck et al. | Jul 2010 | B2 |
7781216 | Thomson | Aug 2010 | B2 |
7794704 | Klimanskaya et al. | Sep 2010 | B2 |
7795025 | Klimanskaya et al. | Sep 2010 | B2 |
7820195 | Kauper et al. | Oct 2010 | B2 |
7824671 | Binder et al. | Nov 2010 | B2 |
7838727 | Lanza et al. | Nov 2010 | B2 |
7846467 | Coroneo et al. | Dec 2010 | B2 |
7855068 | Cao | Dec 2010 | B2 |
7875296 | Binette et al. | Jan 2011 | B2 |
7893315 | Chung et al. | Feb 2011 | B2 |
7910369 | West et al. | Mar 2011 | B2 |
7914147 | Sharifzadeh et al. | Mar 2011 | B2 |
7947498 | Reubinoff et al. | May 2011 | B2 |
7959942 | Cottone | Jun 2011 | B2 |
8808687 | Humayun et al. | Aug 2014 | B2 |
8877489 | Tai et al. | Nov 2014 | B2 |
9248013 | Tai et al. | Feb 2016 | B2 |
9642940 | Tai et al. | May 2017 | B2 |
10188769 | Humayun et al. | Jan 2019 | B2 |
20020081726 | Russell | Jun 2002 | A1 |
20020160509 | Reubinoff et al. | Oct 2002 | A1 |
20030054331 | Fraser et al. | Mar 2003 | A1 |
20030083646 | Sirhan et al. | May 2003 | A1 |
20030231791 | Torre-Bueno et al. | Dec 2003 | A1 |
20050031599 | Kooy et al. | Feb 2005 | A1 |
20050079616 | Reubinoff et al. | Apr 2005 | A1 |
20050106554 | Palecek et al. | May 2005 | A1 |
20050164383 | Reubinoff et al. | Jul 2005 | A1 |
20050214345 | Leng et al. | Sep 2005 | A1 |
20050260747 | Reubinoff et al. | Nov 2005 | A1 |
20060002900 | Binder et al. | Jan 2006 | A1 |
20060034891 | Lawin et al. | Feb 2006 | A1 |
20060078543 | Reubinoff et al. | Apr 2006 | A1 |
20060078545 | Carpenter et al. | Apr 2006 | A1 |
20060104957 | Yiu et al. | May 2006 | A1 |
20060149194 | Conston et al. | Jul 2006 | A1 |
20060234376 | Mistry et al. | Oct 2006 | A1 |
20060235430 | Le et al. | Oct 2006 | A1 |
20060282128 | Tai et al. | Dec 2006 | A1 |
20070106208 | Uber et al. | May 2007 | A1 |
20070128420 | Maghribi | Jun 2007 | A1 |
20070212777 | Reubinoff et al. | Sep 2007 | A1 |
20080140192 | Humayun et al. | Jun 2008 | A1 |
20080243224 | Wallace et al. | Oct 2008 | A1 |
20080299582 | Mandalam et al. | Dec 2008 | A1 |
20090004736 | Reubinoff et al. | Jan 2009 | A1 |
20090074832 | Zussman et al. | Mar 2009 | A1 |
20090075373 | Reubinoff et al. | Mar 2009 | A1 |
20090104695 | Shushan et al. | Apr 2009 | A1 |
20090117639 | Carpenter et al. | May 2009 | A1 |
20090123992 | Chin et al. | May 2009 | A1 |
20090130756 | Klann et al. | May 2009 | A1 |
20090270982 | Torres et al. | Oct 2009 | A1 |
20090291495 | Carpenter et al. | Nov 2009 | A1 |
20090305405 | Carpenter et al. | Dec 2009 | A1 |
20090306772 | Tao et al. | Dec 2009 | A1 |
20100068141 | Kaushal et al. | Mar 2010 | A1 |
20100093091 | Reubinoff et al. | Apr 2010 | A1 |
20100137510 | Seliktar et al. | Jun 2010 | A1 |
20100144033 | Mandalam et al. | Jun 2010 | A1 |
20100173410 | Thomson et al. | Jul 2010 | A1 |
20100189338 | Lin et al. | Jul 2010 | A1 |
20100203633 | Mandalam et al. | Aug 2010 | A1 |
20100211079 | Aramant et al. | Aug 2010 | A1 |
20100241060 | Roizman et al. | Sep 2010 | A1 |
20100272803 | Mistry et al. | Oct 2010 | A1 |
20100299765 | Klimanskaya et al. | Nov 2010 | A1 |
20100317101 | Mandalam et al. | Dec 2010 | A1 |
20110004304 | Tao et al. | Jan 2011 | A1 |
20110027787 | Chuck et al. | Feb 2011 | A1 |
20110053152 | Goldkorn et al. | Mar 2011 | A1 |
20110060232 | Lin et al. | Mar 2011 | A1 |
20110076320 | Coroneo | Mar 2011 | A1 |
20110091927 | Reubinoff et al. | Apr 2011 | A1 |
20110117062 | Klimanskaya et al. | May 2011 | A1 |
20110117063 | Klimanskaya et al. | May 2011 | A1 |
20110177594 | Shushan et al. | Jul 2011 | A1 |
20110189135 | Aharonowiz et al. | Aug 2011 | A1 |
20110236464 | Coffey et al. | Sep 2011 | A1 |
20110256623 | Thomson | Oct 2011 | A1 |
20120009159 | Humayun | Jan 2012 | A1 |
20120083425 | George et al. | Apr 2012 | A1 |
20130137958 | Tai et al. | May 2013 | A1 |
20130143326 | Tai et al. | Jun 2013 | A1 |
20130144399 | Tai et al. | Jun 2013 | A1 |
20140134607 | Lin et al. | May 2014 | A1 |
20150032207 | Humayun et al. | Jan 2015 | A1 |
20150147377 | Humayun et al. | May 2015 | A1 |
20150147810 | Tai et al. | May 2015 | A1 |
20160014192 | Lim et al. | Jan 2016 | A1 |
20160310637 | Tai et al. | Oct 2016 | A1 |
Number | Date | Country |
---|---|---|
2011279250 | Mar 2015 | AU |
1806524 | Jul 2007 | EP |
2593117 | May 2013 | EP |
11-009297 | Jan 1999 | JP |
5876045 | Mar 2016 | JP |
2005082049 | Sep 2005 | WO |
2007132332 | Nov 2007 | WO |
2008098187 | Aug 2008 | WO |
2008129554 | Oct 2008 | WO |
2009127809 | Oct 2009 | WO |
2012004592 | Jan 2012 | WO |
2012009377 | Jan 2012 | WO |
2012149468 | Nov 2012 | WO |
2012149480 | Nov 2012 | WO |
2012149484 | Nov 2012 | WO |
Entry |
---|
Fortin et al., A Model for the Chemical Vapor Deposition of Poly9para-xylylene) (Parylene) Thin Fimls, Chem. Mater. 2002, 14, 1945-1949. |
Giacchino et al. Parylene-Membrane Piezoresistive Pressure Sensors With XEF2-etched Cavity; Sensors, IEEE Conference, pp. 1568-1571. (Year: 2008). |
Lu et al. Highly Flexible, Transparent and Patternable Parylene-C Superhydrophobic Films With High and Low Adhesion; 2011 IEEE 24th International Conference on Micro Electro Mechanical Systems, 2011, pp. 1143-1146. (Year: 2011). |
PCT/US2011/043747 , “International Preliminary Report on Patentability”, dated Jan. 24, 2013, 12 pages. |
PCT/US2012/035654 , “International Preliminary Report on Patentability”, dated Nov. 7, 2013, 7 pages. |
Australian Application No. 2011279250, Office Action dated Jul. 5, 2013, 4 pages. |
Australian Application No. 2015200823, Examination Report dated Jul. 17, 2015, 4 pages. |
European Application No. 11807411.1, Extended European Search Report dated Dec. 16, 2013, 3 pages. |
International Application No. PCT/US2012/035654, International Search Report dated Oct. 29, 2012, 4 pages. |
Japanese Application No. JP 2013-519773, Office Action dated Jun. 8, 2015, 5 pages. |
Tezcaner et al., “In Vitro Characterization of Micropatterned PLGA-PHBV8 Blend Films as Temporary Scaffolds for Photoreceptor Cells,” J Biomed Mater Res vol. 86A, Issue 1, Oct. 23, 2007, pp. 170-181. |
U.S. Appl. No. 14/314,994, Final Office Action dated Mar. 1, 2018, 19 pages. |
U.S. Appl. No. 13/740,069, Final Office Action dated Jun. 19, 2015, 11 pages. |
U.S. Appl. No. 13/740,069, Non-Final Office Action dated Aug. 28, 2014, 11 pages. |
Wang et al., “Fabrication and characterization of a parylene-based three-dimensional microelectrode array for use in retinal prosthesis,” Journal of Microelectromechanical Systems, IEEE Service Center, US, vol. 19, No. 2, Apr. 1, 2010, pp. 367-374. |
12mm Transwell with 0.4 um Pore Polyester Membrane Insert, Retrieved from Internet: URL: http://catalog2. Corning. Com/Lifesciences/en- US/Shopping/PFProductdetails.aspx?productid=3460(Lifesciences ), Jun. 12, 2009. |
U.S. Appl. No. 13/181,279, First Office Action Interview Summary dated Nov. 6, 2013, 35 pages. |
U.S. Appl. No. 13/181,279, Pre-interview first office action dated Apr. 26, 2013, 7 pages. |
U.S. Appl. No. 13/181,279, Restriction Requirement dated Oct. 1, 2012, 9 pages. |
U.S. Appl. No. 13/355,426, Non-Final Office Action dated Oct. 25, 2013, 10 pages. |
U.S. Appl. No. 13/355,426, Restriction Requirement dated May 23, 2013, 6 pages. |
U.S. Appl. No. 13/740,069, Notice of Allowance dated Sep. 29, 2015, 7 pages. |
U.S. Appl. No. 13/740,069, Restriction Requirement dated May 8, 2014, 7 pages. |
U.S. Appl. No. 14/314,994, Non-Final Office Action dated Jun. 6, 2017, 21 pages. |
U.S. Appl. No. 14/498,918, Final Office Action dated Oct. 19, 2015, 12 pages. |
U.S. Appl. No. 14/498,918, Non-Final Office Action dated Mar. 3, 2015, 6 pages. |
U.S. Appl. No. 15/004,796, Notice of Allowance dated Jan. 18, 2017, 10 pages. |
U.S. Appl. No. 61/481,037, Biocompatible substrate for facilitating interconnections between stem cells and target tissues and methods for implanting same, Apr. 29, 2011, 149 pages. |
International Application No. PCT/US2011/043747, International Search Report dated Jul. 24, 2012, 6 pages. |
Algvere, Transplantation of RPE in Age-Related Macular Degeneration: Observations in 141 Disciform Lesions and dry RPE Atrophy, Graefe's Arch Clin Exp Ophthalmol, vol. 235, Issue 3, 1997, pp. 149-158. |
Armstrong et al., The hydrodynamic radii of macromolecules and their effect on red blood cell aggregation, Biophys J., vol. 87, No. 6, Dec. 2004, pp. 4259-4270. |
Binder et al., Transplantation of the RPE in AMD, Progress in Retinal and Eye Research, vol. 26, No. 5, Sep. 2007, pp. 516-554. |
Chang et al., Cell and Protein Compatibility of Parylene-C Surfaces, Langmuir, vol. 23, vol. 23, 2007, pp. 11718-11725. |
Chong et al., Management of inherited outer retinal dystrophies, present and future. Br J Ophthalmol, vol. 83, 1999, pp. 120-122. |
DeBoer et al., Multiparameter Analysis of Primary Epithelial Cultures Grown on Cycloprore Membranes, Journal of Histochemistry and Cytochemistry, vol. 42, Issue 2, 1994, pp. 277-282. |
Hannachi et al., Cell Sheet Technology and Cell Patterning for Biofabrication, Biofabrication, vol. 1, No. 2, Jun. 10, 2009, 13 pages. |
Hsiao et al., Microfluidic system for formation of PC-3 prostate cancer co-culture spheroids, Biomaterials, vol. 30, 2009, pp. 3020-3027. |
Huang et al., Stem cell-based therapeutic applications in retinal degenerative diseases, Stem Cell Reviews and Reports, Humana Press Inc., NY. vol. 7, No. 2, Sep. 22, 2009, pp. 434-445. |
Jackson et al., Human retinal molecular weight exclusion limit and estimate of species variation, Invest Ophthalmol Vis Sci, vol. 44, No. 5, 2003, pp. 2141-2146. |
Kannan et al., Stimulation of Apical and Basolateral VEGF-A and VEGF-C Secretion by 148 Oxidative Stress in Polarized Retinal Pigment Epithelial Cells, Molecular Vision, vol. 12, 2006, pp. 1649-1659. |
Lavik et al., Fabrication of Degradable Polymer Scaffolds to Direct the Integration and Differentiation of Retinal Progenitors, Biomaterials, vol. 26, Issue 16, Jun. 2005, pp. 3187-3196. |
Lee et al., Determination of human lens capsule permeability and its feasibility as a replacement for Bruch's membrane, Biomaterials, vol. 27, No. 8, Mar. 2006, pp. 1670-1678. |
Liu et al., A 3-D microfluidic combinatorial cell culture array, IEEE Proc. of MEMS, 2009, pp. 427-430. |
Lu et al., A 3-D parylene scaffold cage for culturing retinal pigment epithelial cells, Micro Electio Mechanical Systems (MEMS), 2012, pp. 741-744. |
Lu et al., A study of the autofluorescence of parylene materials for 1-1TAS applications, Lab Chip, vol. 10, 2010, pp. 1826-1834. |
Lu et al., Mesh-supported submicron parylene-C membranes for culturing retinal pigment epithelial cells, Biomed Microdevices, vol. 14, 2002, pp. 659-667. |
Lu et al., Semipermeable parylene membrane as an artificial bruch's membrane, International Solid-State Sensors, Actuators and Microssytems Conference, 2011, pp. 950-953. |
Lu et al., Thin collagen film scaffolds for reitnal epithelial cell culture, Biomaterials, vol. 28, 2007, pp. 1486-1494. |
Lu et al., Ultrathin parylene-C semipermeable membranes for biomedical applications, IEEE International Micro Electio Mechanical Systems, Jan. 2011, pp. 505-508. |
Morris et al., Cryopreservation of murine embryos, human spermatazoa and embryonic stem cells using a liquid nitrogen-free controlled rate freezer, Reproductive Biomedicine Online, vol. 13, vol. 3, 2006, pp. 421-426. |
Neeley et al., A Microfabricated Scaffold for Retinal Progenitor Cell Grafting, Biomaterials, vol. 29, Issue 4, Feb. 2008, pp. 418-426. |
Pereira-Rodrigues et al., Modulation of hepatocarcinoma cell morphology and activity by parylene-C coating on PDMS, PLoS One, vol. 5, No. 3, 2010, 13 pages. |
Redenti et al., Engineering Retinal Progenitor Cell and Scrollable poly(glycerol-sebacate) 155 composites for Expansion and Subretinal Transplantation, Biomaterials, vol. 30, Issue 20, Apr. 9, 2009, pp. 3405-3414. |
Redenti et al., Retinal Tissue Engineering using Mouse Retinal Progenitor Cells and a Novel Biodegradable, Thin-Film Poly(e-caprolactone) Nanowire Scaffold, J Ocul Biol. Dis Infor., vol. 1, Issue 1, May 22, 2008, pp. 19-29. |
Roy et al., Silicon nanopore membrane technology for an implantable artificial kidney, Proc. of Transducers, 2009, pp. 755-760. |
Sodha et al., A Microfabricated 3-D stem Cell Delivery Scaffold for Retinal Regenerative Therapy, Thesis, Master of Engineering in Biomedical Engineering, Massachusetts Institute of Technology, Jun. 2009. |
Sodha et al., Microfabrication of a Three-Dimensional Polycaprolactone Thin-Film Scaffold for 158 Retinal Progenitor Cell Encapsulation, J Biomater Sci Polym Ed., vol. 22, Issue 4-6,, Jun. 21, 2011, pp. 443-456. |
Stanzel et al., Culture of Human RPE from Aged Donors on a Potential Bruch's Membrane Prosthesis, Invest Ophthalmol Vis Sci, vol. 47. 2006. |
Stanzel et al., Towards Prosthetic Replacement of Bruch's Membrane: Comparison of Polyester and Electrospun Nanofiber Membranes, Invest Ophthalmol Vis Sci, vol. 48, 2007. |
U.S. Appl. No. 14/314,994, Notice of Allowance dated Sep. 11, 2018, 9 pages. |
Number | Date | Country | |
---|---|---|---|
20160361463 A1 | Dec 2016 | US |
Number | Date | Country | |
---|---|---|---|
61566965 | Dec 2011 | US |
Number | Date | Country | |
---|---|---|---|
Parent | 14498918 | Sep 2014 | US |
Child | 15184934 | US | |
Parent | 13355426 | Jan 2012 | US |
Child | 14498918 | US | |
Parent | 15184934 | US | |
Child | 14498918 | US | |
Parent | 14314994 | Jun 2014 | US |
Child | 15184934 | US |